{
    "nctId": "NCT02323399",
    "officialTitle": "Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (\u226512 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia",
    "inclusionCriteria": "1. Subject's age is between \u226512 and 16 years, inclusive\n2. Subject is scheduled for a procedure that requires general or neuraxial anesthesia\n3. Subjects must have normal or clinically acceptable physical exam\n4. Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure \u2264128/78 mmHg (sitting, after 5 minutes of rest)\n5. Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1\n6. Subject's parent or legal guardian gives informed consent and subject gives assent.\n* Must have minimum age of 12 Years\n* Must have maximum age of 16 Years",
    "exclusionCriteria": "1. Subject has a contraindication to vasoconstrictor therapy for control of blood pressure\n2. Subject has participated in other clinical trials for investigational drugs and/or devices within 30 days prior to enrollment\n3. Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures\n4. Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration\n5. Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody\n6. Subjects taking antihypertensive medication\n7. Subject is moribund (death is likely to occur in less than 48 hours)\n8. Females who are pregnant, nursing or unwilling to use/practice adequate contraception."
}